Protein / target
Large ribosomal subunit protein uL4
Protein at a glance
Biological role
RNA-binding transcription regulator activity
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
One of the primary rRNA binding proteins, this protein initially binds near the 5'-end of the 23S rRNA (PubMed:3298242). It is important during the early stages of 50S assembly (PubMed:3298242). It makes multiple contacts with different domains of the 23S rRNA in the assembled 50S subunit and ribosome (PubMed:6170935, PubMed:7556101)
Domains and Gene Ontology detail (19)Hide
Gene Ontology
- Ccytoplasm
- Ccytosol
- Ccytosolic large ribosomal subunit
- Clarge ribosomal subunit
- FDNA binding
- Fendoribonuclease inhibitor activity
- FmRNA 5'-UTR binding
- FRNA-binding transcription regulator activity
- FrRNA binding
- Fstructural constituent of ribosome
- Ftranslation repressor activity
- Pcytoplasmic translation
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Transcriptional regulation
- ·RNA-binding transcription regulator activity
- ·DNA-templated transcription termination
- ·negative regulation of DNA-templated transcription
- ·transcriptional attenuation
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 8 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Industry developmentFe-doped BiVO4/g-C3N4 heterojunction for efficient tetracycline degradation under low-intensity UV irradiation
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- Label change
Label change: DOXYCYCLINE (ANDA207757)
- New publicationImpact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children.
- New publicationGuidelines of care for the management of acne vulgaris.
- New publicationNew Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.
- Safety communication
Drug Safety Update: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
- Safety communication
Drug Safety Update: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
- New publicationRisk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
- Label change
Label change: DOXYCYCLINE (ANDA207757)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.